To review the role of transdermal nicotine as an aid to smoking cessation.
DATA SOURCES:
A MEDLINE search was performed that included clinical studies published in English involving transdermal nicotine; references used in those articles were screened for additional published information.
STUDY SELECTION:
Published clinical trials were reviewed with particular emphasis on controlled trials that evaluated safety and efficacy.
DATA SYNTHESIS:
Transdermal nicotine therapy has been shown to be a safe and effective pharmacologic aid in a smoking cessation program when used in conjunction with a psychologic or behavior support system. Habitrol, Nicoderm, Nicotrol, and PROSTEP differ in some characteristics (i.e., delivery systems, total nicotine content and amount absorbed, rate of delivery, recommended duration of application); however, the clinical implication of these differences has not been determined.
CONCLUSIONS:
Transdermal nicotine is effective for patients who are motivated to quit smoking and receive concomitant behavior support.
Get full access to this article
View all access options for this article.
References
1.
Centers for Disease Control. Cigarette smoking among adults—United States, 1990. MMWR1992; 41: 354–5, 361–2.
2.
BenowitzNL. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med1988; 319: 1318–30.
3.
PetersJA. Nicotine replacement therapy in cessation of smoking. Mayo Clin Proc1990; 65: 1619–23.
NieodPRehrRWinnifordMDCampbellWBFirthBGHillisLDAcute systemic and coronary hemodynamic and serologic responses to cigarette smoking in long term smokers with atherosclerotic coronary artery disease. J Am Coll Cardiol1984; 4: 964–71.
10.
WestRJRussellMA. Cardiovascular and subjective effects of smoking before and after 24 hr of abstinence from cigarettes. Psychopharmacology1987; 92: 118–21.
11.
Centers for Disease Control. The health consequences of smoking. Nicotine addiction. A report from the Surgeon General. US Department of Health and Human Services, Public Health Service, Center for Health Promotion and Education, Office on Smoking and Health. Rockville, MD: US Government Printing Office, 1988 (223-672/0).
12.
JohansonCFischmanMW. The pharmacology of cocaine related to its abuse. Pharmacol Rev1989; 41: 3–52.
13.
WesnesKWarburtonDM. Smoking, nicotine and human performance. Pharmacol Ther1983; 21: 189–208.
14.
WackJTRodinJ. Smoking and its effects on body weight and the systems of caloric regulation. Am J Clin Nutr1982; 35: 366–80.
15.
HenningfieldJEGoldbergSR. Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav1983; 19: 989–92.
16.
FioreMCJorenbyDEBakerTBKenfordSL. Tobacco dependence and the nicotine patch. Guidelines for effective use. JAMA1992; 268: 2687–94.
17.
BenowitzNL. Pharmacodynamics of nicotine: implications for rational treatment of nicotine addiction. Br J Addict1991; 86: 495–9.
18.
GloverED. Transdermal nicotine patch for smoking cessation (letter). N Engl J Med1992; 326: 344.
19.
DaughtonDMHeatleySAPrendergastJJCauseyDKnowlesMRolfCNEffect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. Arch Intern Med1991; 151: 749–52.
20.
BenowitzNLChanKDenaroCPJacobP. Stable isotope method for studying transdermal drug absorption: the nicotine patch. Clin Pharmacol Ther1991; 50: 286–93.
21.
BannonYBCorishJCorriganOLDevaneJGKavanaghMMulliganSTransdermal delivery of nicotine in normal healthy volunteers: a single dose and multiple dose study. Eur J Clin Pharmacol1989; 37: 285–90.
22.
GorslineSOkerholmRARolfCNMoosCDHwangSS. Comparisons of plasma nicotine concentrations after application of Nicoderm to different skin sites. J Clin Pharmacol1992; 32: 576–81.
23.
OldendorfWH. Lipid solubility and drug penetration in the blood brain barrier. Proc Soc Exp Biol Med1974; 147: 813–5.
24.
BenowitzNLJacobPJonesPRosenbergJJ. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther1982; 221: 372–86.
25.
RosenbergJBenowitzNLJacobPWilsonKM. Disposition kinetics and effects of intravenous nicotine. Clin Pharmacol Ther1980; 28: 517–22.
26.
FeyerabendCIngsAMRussellMA. Nicotine pharmacokinetics and its application to intake from smoking. Br J Clin Pharmacol1985; 19: 239–47.
27.
KyerenatenGADamianoMDDvorchikBHVessellES. Smoking induced changes in nicotine disposition: application of a new HPLC assay for nicotine and its metabolite. Clin Pharmacol Ther1982; 32: 769–80.
28.
LuckWNauH. Exposure of the fetus, neonate, and nursed infants to nicotine and cotinine in maternal smoking (letter). N Engl J Med1984; 311: 672.
29.
LuckWNauH. Nicotine and cotinine concentrations in serum and milk of nursing smokers. Br J Clin Pharmacol1984; 18: 9–15.
30.
GorrodJWJennerP. The metabolism of tobacco alkaloids. Essays Toxicol1975; 6: 35–78.
31.
KimKSBorzellaJFBowmanERMcKennisH. Effects of some nicotine metabolites and related compounds on isolated smooth muscle. J Pharmacol Exp Ther1968; 161: 59–69.
32.
BenowitzNLKuytFJacobPIIIJonesRTOsmanAL. Cotinine disposition and effects. Clin Pharmacol Ther1983; 34: 604–11.
MullerPHAbelinTHEhrsamRImhofPHowaldH. The use of transdermal nicotine in smoking cessation. Lung1990; 168 (suppl): 445–53.
36.
Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation: six month results from two multicenter controlled clinical trials. JAMA1991; 266: 3133–8.
37.
MulliganSCMastersonJGDevaneJGKelleyJG. Clinical and pharmacokinetic properties of a transdermal nicotine patch. Clin Pharmacol Ther1990; 47: 331–7.
38.
HurtRDLaugerGGOffordKPKottkeTEDaleLC. Nicotine-replacement therapy with use of a transdermal nicotine patch—a randomized double-blind placebo-controlled trial. Mayo Clin Proc1990; 65: 1529–37.
39.
TønnesenPNørregaardJSimonsenKSäweU. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation (letter). N Engl J Med1991; 325: 311–5.
40.
TønnesenPNørregaardJSimonsenKSäweU. Transdermal nicotine patch for smoking cessation (letter). N Engl J Med1992; 326: 345.
41.
BuchkremerGBentsHMinnekerEOpitzK. Combination of behavioral smoking cessation therapy with transdermal nicotine substitution: long term effects. Excerpta Medica1988; 780: 857–60.
42.
BuchkremerGBentsHHorstmannMOpitzKTolleR. Combination of behavioral smoking cessation with transdermal nicotine substitution. Addict Behav1989; 14: 229–38.
43.
KrumpePMelaniNAdlerJRamoorthySAsadiSCorwinN. Efficacy of transdermal nicotine administration as an adjunct for smoking cessation in heavily addicted smokers (abstract). Am Rev Respir Dis1989; 139: A337.
44.
AbelinTBuehlerAMullerPVesanenKImhofPR. Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet1989; 1: 7–10.
45.
Surgeon General. The health consequences of smoking in women: a report of the Surgeon General, 1983. Washington, DC: US Government Printing Office; 1983: 191–249. US Department of Health and Human Services publication 410–889/1284.
46.
BenowitzNL. Nicotine replacement therapy during pregnancy. JAMA1991; 266: 3174–7.
HwangSLeeL. Heart attacks in patch users still smoking. Wall Street Journal1992 June 19; Sect. B:l.
49.
KaurSAliB. Stimulation of drug and carcinogen metabolism by prolonged oral tobacco consumption. Biochem Pharmacol1982; 31: 1595–7.
50.
LeeBLBenowitzNLJacobP. Cigarette abstinence, nicotine gum and theophylline disposition. Ann Intern Med1987, 106: 553–5.
51.
Boston Collaborative Drug Surveillance Program. Decreased clinical efficacy of propoxyphene in cigarette smokers. Clin Pharmacol Ther1973; 14: 259–63.
52.
PowellJRThiercelinJFVozekSSamsomLRiegelmanS. The influence of cigarette smoking and sex on theophylline disposition. Am Rev Respir Dis1977; 116: 17–23.
53.
LinnoilaMGeorgeLGuthrieSLeventhalB. Effect of alcohol consumption and cigarette smoking on antidepressant levels of depressed patients. Am J Psychiatry1981; 138: 841–2.
54.
KlempPStabergBMadstadSLolendorfK. Smoking reduces insulin absorption from subcutaneous tissue. Br Med J1982; 284: 237.
55.
Collaborative Group for the Study of Stroke in Young Women. Oral contraceptives and stroke in young women: associated risk factors. JAMA1975; 231: 718–22.
56.
SwettC. Drowsiness due to chlorpromazine in relation to cigarette smoking: a report from Boston Collaborative Drug Surveillance Program. Arch Gen Psychiatry1974; 31: 211–4.
57.
HatsukamiDKPickensRWKrahnDMalinSLuknicA. Effect of nicotine gum on the tobacco withdrawal syndrome. Psych Pharmacol1984; 83: 82–7.
58.
SchneiderNGJarvikMEForsytheABReadLLElliotMLSchweigerA. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. Addict Behav1983; 8: 253–61.
59.
LamWSzePCSacksHSChalmersTL. Meta-analysis of randomized controlled trials of nicotine chewing gum. Lancet1987; 2: 27–9.
60.
Meier-LammermanEMeyerMBolaskeiPL. Differences between transdermal nicotine application and nicotine chewing gum in combination with behavioral therapy in smoking cessation (abstract). Eur Respir J1991; 4 (suppl 14): 502s.
61.
GorslineJBenowitzNLRolfCNGuptaSKGaraudJJ. Comparison of plasma nicotine concentrations for nicotine transdermal system, cigarette smoking and nicotine polacrilex (abstract). Clin Pharmacol Ther1992; 51: 129.
